For example, the prostate cancer medicine, abiraterone, was routinely available in Wales from February 2012 following appraisal by AWMSG.
Fel y cyhoeddwyd mewn datganiad gan y Dirprwy Weinidog Iechyd, rhoddwyd model ymateb clinigol newydd ar waith yng Nghymru o 1 Hydref 2015.